HIROTSU Bioscience CEO Talks Nasdaq Strategy at BEYOND 2020 “INNOVATION DAY”
2025.03.21
Tokyo, Japan – [February 28, 2025] – HIROTSU Bioscience CEO Takaaki Hirotsu participated as a panelist at BEYOND 2020 NEXT FORUM “INNOVATION DAY”, held on February 28 at Tokyo Innovation Base. This high-profile event brought together leading innovators, entrepreneurs, and policymakers to drive forward Japan’s post-2020 transformation.
“INNOVATION DAY” featured three key sessions: “NASDAQ Success Strategies,” “The Power of Social Impact,” and “Entertainment NEXT.” Dr. Hirotsu participated in the NASDAQ Success Strategies panel, sharing insights on:
- N-NOSE, the company’s groundbreaking nematode-based cancer detection technology.
- Opportunities in the global cancer diagnostics market.
- Why HIROTSU Bioscience is targeting a Nasdaq listing over domestic exchanges.
As HIROTSU Bioscience positions itself as a leader in early cancer detection, its Nasdaq aspirations signal a strategic push for global expansion and investor engagement. The company’s pioneering N-NOSE testing platform has the potential to disrupt traditional diagnostics, offering a non-invasive, cost-effective, and highly sensitive approach to early cancer screening.
The full session was streamed live and is available for viewing here (Japanese only). – insert link
For more information about BEYOND 2020 NEXT FORUM, visit Tokyo Headline. – insert link